“…They are, for example, critically involved the clearance of Aβ thus being putative molecular targets for AD treatment (Cirrito et al, 2005; Gosselet et al, 2013; Kim et al, 2013; Koldamova et al, 2010; Krohn et al, 2011; Pahnke et al, 2013; Pahnke et al, 2009; Pahnke et al, 2008; Scheffler et al, 2012; Schumacher et al, 2012; Vogelgesang et al, 2002; Vogelgesang et al, 2004). Dysfunction of ABCB1 has been associated with Parkinson’s disease, progressive supranuclear palsy (PSP), multi-systems atrophy (MSA) and very recently genetic associations with depressive disorders were found (Bartels et al, 2008; Enokido et al, 2014; Li et al, 2014; Santos et al, 2014). In accordance with their function as “gatekeepers” at the BBB, ABCB1 and ABCC1 are localized in both the luminal and abluminal membranes of brain capillary endothelial cells, in adjacent pericytes and astrocytes as well as in choroid plexus epithelia and ventricular ependyma (for reviews see (Ballerini et al, 2002; Bendayan et al, 2002; Gazzin et al, 2008; Keep and Smith, 2011; Thiebaut et al, 1987; Wolf et al, 2012)).…”